New cancer clinical trial: Iovance Alliance: LN-145 Across Multiple Tumor Types

Published on: February 28, 2018 at 12:00PM
Conditions:   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Female Genital Organs
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: LN-145;   Drug: IL-2;   Drug: Mesna;   Behavioral: Questionnaires
Sponsors:   M.D. Anderson Cancer Center;   Iovance Biotherapeutics, Inc.
Not yet recruiting
http://ift.tt/2F5F9ZH